Ones To Watch News
Refine Search
Biotechnology
US drug developer Apellis Pharmaceuticals was upbeat about clinical trial results for its pegcetacoplan, but investors thought otherwise, sending the firm’s shares down 32% to $38.00 in after hours on Thursday. 10 September 2021
Biotechnology
Twist Bioscience Corp saw its shares increase 6% to $117.93 today, after it announced a broad-based research collaboration with German family-owned drug major Boehringer Ingelheim to use Twist’s proprietary antibody libraries to discover therapeutic antibodies against multiple targets provided by Boehringer Ingelheim. 9 September 2021
Biotechnology
Shares of Centessa Pharmaceuticals were up 17.6% at $24.76 in early trading today after, together with subsidiary ApcinteX, it announced positive top-line results from the Phase IIa part of AP-0101, the six-month repeat dose portion of its ongoing first-in-human proof-of-concept study evaluating SerpinPC in severe hemophilia A and B patients. 9 September 2021
Biotechnology
Dutch biotech firm ProQR Therapeutics has inked a global licensing and research collaboration with Eli Lilly, worth over a billion dollars in the best case scenario. 9 September 2021
Biotechnology
Sino-American company Brii Birosciences today announced that it is committing an additional $100 million to advance global regulatory filings and commercial efforts for its investigational SARS-CoV-2 (virus that causes COVID-19) combination therapy, BRII-196/BRII-198. 7 September 2021
Biotechnology
Lumevoq (lenadogene nolparvovec) has been granted Promising Innovative Medicine (PIM) designation by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). 7 September 2021
Biotechnology
Swedish biotech pairing Alligator Bioscience and Scandion Oncology have concluded a research collaboration, describing its outcome as positive. 2 September 2021
Biotechnology
Precision BioSciences and UK biotech Tiziana Life Sciences have entered an exclusive license agreement to explore Tiziana's foralumab, a fully human anti-CD3 monoclonal antibody (MAb), as an agent to induce tolerance of allogeneic CAR T-cells to potentially improve the clinical outcome of CAR-T cell therapy. 2 September 2021
Biotechnology
Brukinsa (zanubrutinib) has received approval from the US Food and Drug Administration (FDA) for the treatment of adult patients with Waldenström’s macroglobulinemia (WM). 2 September 2021
Biotechnology
Chinese biopharma firm Innovent Biologics and US biotech Bolt Biotherapeutics have announced a drug research and development collaboration to develop three new anti-cancer therapeutic immune-stimulating antibody conjugate (ISAC) candidates. 31 August 2021
Biotechnology
Shares of Belgian cell therapy developer Bone Therapeutics tumbled 34.6% 1.73 euros by early afternoon trading, after the company announced that the Phase III knee osteoarthritis study with its enhanced viscosupplement JTA-004 did not meet the primary and consequently the key secondary endpoints. 30 August 2021
Pharmaceutical
Following a positive opinion from the European Medicines Agency’s human health committee in June, the European Commission (EC) has rubber-stamped its marketing authorization for Voxzogo (vosoritide), a once daily injection to treat achondroplasia in children from the age of two until growth plates are closed, which occurs after puberty when children reach final adult height. 28 August 2021
Biotechnology
USA-based oncology specialist Sesen Bio, in a filing with the US Securities and Exchange Commission (SEC), revealed that it has withdrawn its marketing authorization application (MAA) to the European Medicines Agency for Vysyneum (oportuzumab monatox) for the treatment of Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC). 27 August 2021
Biotechnology
Sino-American company Brii Biosciences has announced positive data from the ACTIV-2 Phase III trial evaluating the combination of BRII-196 and BRII-198 in non-hospitalized COVID-19 patients. 26 August 2021
Biotechnology
US drugmaker Eagle Pharmaceuticals has entered into a worldwide licensing agreement with Swiss biotech Combioxin for the commercial rights to CAL02, an antitoxin agent ready for Phase IIb/III development for the treatment of severe pneumonia in combination with traditional antibacterial drugs. 26 August 2021
Biotechnology
UK-based T cell receptor (TCR) biotech firm Immunocore yesterday announced that regulators in the USA and European Union have each accepted applications for the approval of tebentafusp (IMCgp100) for the treatment of HLA-A*02:01-positive adult patients with metastatic uveal melanoma (mUM). 25 August 2021
Biotechnology
Shares of Denmark’s biopharma company Orphazyme rose 12.4% to $5.63 on Monday, as it announced that positive results from a Phase II/III trial of arimoclomol, an investigational heat-shock protein amplifier, in Niemann-Pick disease type C (NPC) have been published in the peer-reviewed Journal of Inherited Metabolic Disease (JIMD). 24 August 2021
Pharmaceutical
Ireland-incorporated drug developer Theravance Biopharma saw its shares plummet 27.5% to $10.33 pre-market today, after it announced top-line results from its Phase IIb dose-finding induction study of izencitinib, an orally administered, gut-selective pan-Janus kinase (JAK) inhibitor in development for the treatment of ulcerative colitis. 24 August 2021
Pharmaceutical
The US Food and Drug Administration has approved Korsuva (difelikefalin) for injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis, said Cara Therapeutics. 24 August 2021
Biotechnology
Norwegian clinical-stage biotech BerGenBio has announced the appointment of Martin Olin as its new chief executive, effective September 8, 2021. 24 August 2021
Biotechnology
Epitopea, a UK and Canada-based cancer immunotherapeutics company, has partnered with nucleic acid delivery specialist Genevant Sciences to develop new RNA-based therapies targeting proprietary tumor antigens. 20 December 2024
Pharmaceutical
US biotech Assembly Biosciences has announced an equity investment of $20.1 million by Gilead Sciences to purchase additional common stock in the company and an amendment to their collaboration to advance the research and development of novel antiviral therapies with $10 million in accelerated funding. 20 December 2024
Pharmaceutical
Privately-held Xcovery Holdings, an oncology-focused pharma company, has announced that the US Food and Drug Administration (FDA) has approved Ensacove (ensartinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). 19 December 2024
Biotechnology
Privately-held biotech Ottimo Pharma today announces the completion of a Series A financing round of over $140 million. 19 December 2024
Biotechnology
Safi Biotherapeutics, a specialist in stem-cell derived red blood cell products, has received Rare Pediatric Disease designation and Orphan Drug designation from the US regulator. 19 December 2024
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze